Leqvio FDA Approval
We are building on our strength in cardiovascular to
fundamentally improve and extend patients' lives
2015
Entresto
sacubitril/valsartan
Essential first
choice for chronic
heart failure
~15m
patients
2021
~2025
LEQVIO pelacarsen
inclisiran
Potential to tackle
LDL-C in
ASCVD at scale
(TQJ230)
Potential to lower
CV risk for people
with elevated Lp(a)
~60m
patients
High unmet need: CV
disease leading cause
of mortality
Strong worldwide
commercial and
scientific presence
Deep understanding of
customer needs across
primary and specialty care
LDL-C - Low Density Lipoprotein Cholesterol ASCVD Atherosclerotic Cardiovascular Disease CV - Cardiovascular Lp(a) Lipoprotein(a) Note: Dates refer to US approval for EntrestoⓇ and LeqvioⓇ, to submission for pelacarsen.
Population numbers refer to US & EU5 (Germany, France, Spain, Italy, UK). Source: Decision Resources Group.
5
Leqvio® FDA Approval | December 23, 2021 | Novartis Investor Presentation
1 NOVARTIS | Reimagining MedicineView entire presentation